We are pleased to announce that the Series A investment round for KIC Ventures is now open. This round presents a rare opportunity to join early in one of the few vertically integrated private equity platforms focused exclusively on transforming spine and pain care.

KIC Ventures is the parent company of four category-defining technologies:

· AxioMed – Viscoelastic Total Disc Replacement

· Inspan – Interspinous Fixation for Spinal Fusion

· Sacrix – Percutaneous SI Joint Fusion

· NanoFUSE – Orthobiologic Fusion Technology

Together, these form the foundation of our vision for Less Exposure Spine Surgery(LESS)- minimally invasive procedures designed for outpatient spine care, ASC adoption, and faster patient recovery.

This Series A raise will support:

· Final clinical trials and regulatory milestones for AxioMed (FDA approval expected 2025)

· Commercial expansion across global markets

· Lab training, proctorships, and education platforms

· R&D for next-generation spine and pain technologies

Why Join Early?

Investors who join early in the round will gain strategic access to:

· A diversified, clinically validated portfolio with multiple revenue pathways

· A physician-aligned ecosystem, where many clinical users are also shareholders

· Significant upside potential, tied to both FDA inflection points and strategic exit opportunities

· Eligibility for Self-Directed IRA (SDIRA) participation, allowing tax-advantaged investing

Unlike single-product plays, KIC Ventures offers equity in a full-stack medtech platform, one already generating impact in operating rooms and training labs nationwide. We're not betting on future relevance; we're building it.

If you're an accredited investor looking to invest in a company with real traction, real products, and a real mission, KIC Ventures is your entry point into the future of spine.

Reach out to day to know more: Schedule a Call